Romosozumab versus denosumab for bone loss from long-term glucocorticoid use, at 6 years
Compares romosozumab and denosumab on bone density in adults taking long-term glucocorticoids.
Key facts
- Who runs it
- Tuen Mun Hospital
- Where
- Hong Kong, Hong KongSee the site
- Trial code
- Registry title
- Romosozumab Versus Denosumab In Glucocorticoid-induced Osteoporosis: An Extended Observation Of a Clinical Trial at 6 Years
- Status
- Not yet recruiting
- Phase
- Phase 4
- People taking part
- 54 people, planned
- Started
- 1 Sept 2026
- Expected to end
- 1 Dec 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Romosozumab
- Denosumab
- Record updated
- 12 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people already in an earlier trial of romosozumab versus denosumab for bone loss caused by long-term glucocorticoids. They must have stayed on denosumab after month 48 and be willing to have a repeat bone scan (DXA) at 6 years.
- Age
- 18 years and older
- Sex
- All sexes can join
- Disease stage
- Bone loss or osteoporosis caused by long-term glucocorticoids (steroid medicines)
- Earlier treatment
- Must have continued 6-monthly denosumab injections under the skin after month 48, in either the romosozumab or the denosumab group of the earlier trial
Main reasons for not taking part
- Refuses to stay on denosumab after month 48
- Takes other osteoporosis drugs after month 48
- Prednisolone is planned to be reduced or stopped after month 48
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- patients who are continued on 6-monthly subcutaneous injection of DEN in either the ROMO or DEN arms after month 48; (2) those who are willing to have a repeat DXA assessment at the end of 6 years
Who cannot take part
- patients who are maintained on other anti-osteoporotic drugs after month 48
- patients who refuse to be maintained on denosumab after month 48
- patients in whom prednisolone is planned to be tapered or discontinued after month 48
Where in Hong Kong
- Tuen Mun HospitalHong Kong, Hong KongContact: Chi Chiu Mok, MD, FRCPNot yet recruiting
About the trial
What the trial wants to find out
This is an extended observation study of a RCT comparing the efficacy of romorozumab and denosumab in high-risk patients using long-term glucocorticoids. In the romosozumab arm, patients were shifted to denosumab after the first year. The denosumab arm of patients were continued on denosumab. This study aims to look at the bone mineral density changes in both groups of patients after 6 years.
The 2 groups in the trial
- romosozumabExisting treatment, for comparison
romosozumab for 12 months, followed by denosumab
Treatment: Romosozumab and Denosumab
- denosumab aloneExisting treatment, for comparison
Treatment: Denosumab
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Romosozumab Versus Denosumab In Glucocorticoid-induced Osteoporosis: An Extended Observation Of a Randomized Controlled Trial At 6 Years
- Plain-language title
- Romosozumab versus denosumab for bone loss from long-term glucocorticoid use, at 6 yearsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 12 August 2026